Jump to content

Spiramide

From Wikipedia, the free encyclopedia
(Redirected from AMI-193)
Spiramide
Clinical data
ATC code
  • none
Identifiers
  • 8-[3-(4-Fluorophenoxy)propyl]-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H27FN3O2
Molar mass384.475 g·mol−1
3D model (JSmol)
  • c2cc(F)ccc2OCCCN3CCC1(CC3)N(CNC1=O)c4ccccc4
  • InChI=1S/C22H26FN3O2/c23-18-7-9-20(10-8-18)28-16-4-13-25-14-11-22(12-15-25)21(27)24-17-26(22)19-5-2-1-3-6-19/h1-3,5-10H,4,11-17H2,(H,24,27)
  • Key:FJUKDAZEABGEIH-UHFFFAOYSA-N
  (verify)

Spiramide (developmental code name AMI-193) is an experimental antipsychotic that acts as a selective 5-HT2A, 5-HT1A, and D2 receptor antagonist. It has negligible affinity for the 5-HT2C receptor.[1][2][3]

References

[edit]
  1. ^ Czoty PW, Howell LL (October 2000). "Behavioral effects of AMI-193, a 5-HT(2A)- and dopamine D(2)-receptor antagonist, in the squirrel monkey". Pharmacology Biochemistry and Behavior. 67 (2): 257–64. doi:10.1016/S0091-3057(00)00321-X. PMID 11124389. S2CID 36132685.
  2. ^ Luparini MR, Garrone B, Pazzagli M, Pinza M, Pepeu G (November 2004). "A cortical GABA-5HT interaction in the mechanism of action of the antidepressant trazodone". Progress in Neuro-psychopharmacology & Biological Psychiatry. 28 (7): 1117–27. doi:10.1016/j.pnpbp.2004.05.046. PMID 15610924. S2CID 24076522.
  3. ^ Hamada K, Yoshida M, Isayama H, Yagi Y, Kanazashi S, Kashihara Y, Takeuchi K, Yamaguchi I (November 2007). "Possible involvement of endogenous 5-HT in aggravation of cerulein-induced acute pancreatitis in mice". Journal of Pharmacological Sciences. 105 (3): 240–50. doi:10.1254/jphs.FP0071049. PMID 17965538.